We need a new target (for CAR-T therapy) to kill only malignant B Cells not all B cells including healthy ones. Or maybe a way to render the Engineered T cells ineffective after they completed the task (no malignant B cells determined by MRD negative). I know it's preferable to be alive even though receiving IVIG every month, but is it possible to return a person to whole after CART19?
I know it is early for CAR-T technology. This being one of the treatments to activate our immune system to fight cancer tumors. But if I am not mistaken the response rate for CLL patients is less than 40%. Acute ALL might be 80%. But Dr. Byrd told me last visit that after Acalabrutinib this would be a treatment he might recommend for me.
The other Immune system treatments are known as checkpoint inhibitors. Keytruda is an example.....
I was thinking this is what Jimmy Carter was treated with, to cure his melanoma. Also some radiation treatment as well. I don't think there has been much testing of checkpoint inhibitors in CLL to date. But the direction these medications take us are better for sure.
Have you any info (update) on ROR1. I viewed some "Tom Kipps video" and other posts on this as a target in CLL. Than I think there was a sale in the technology development of this for use in CAR-T. Also was a target for Vaccine (I think) for use in CLL. Maybe it was found to not work, and went away quietly.
Monthly IVIG isn't so bad if everything else is going well. But I think this treatment is in it's infancy. Who knows how far they will be able to advance it.
I had it last year. Twelve months later my bloods are normal. I feel wonderful. The treatment is not for the faint of heart. I had all the side effects but made it through. Very glad I did it.
Generally speaking the Holy Grail is a treatment that only targets the malignant cells, leaving the good B cells intact... that way, you could selective kill the CLL, and leave the immune system uneffected.
Most patients die from secondary opportunistic infections, as the immune system collapses... or from bone marrow infiltration...
Either way, removing of just the malignant cells would provide a life long control... and in theory, a cure...
Listen to Croce... you need a one two punch... again like everything in CLL, it works for some but not all...
there are two different approaches, cirmtuzumab (ROR1) is a monoclonal, and MDA has a Car-T targeted to ROR1.
I read something that ROR1 also is found elsewhere, but it was just mentioned a few years ago.. I don't recall the context.
My money is on acalabrutinib (ACP-196) and venetoclax in combination, and perhaps a combo from TG... Gilead has irons in the fire as well, they could mount a combo from their pipeline...
But we are looking 3-5 years out..at least to the clinic...
It was... Dr. Gribbons was not able to get a firm response on Origins of Malignancy. But on Dr. Gribbons video at approx 2mins 40 secs he mentions Dr. Croce's findings. I read that to mean there must be more to Mir 15 - 16 in CLL. Maybe nothing, but dashed my hopes.
CAR-T is designed to go after a target. The targets are the small proteins or whatever we call it (antigens is what Dr, Croce referred to it), that are on a B-cell. Original design CAR-T would go after CD19 and would kill cells having this (CD19) on the cell. Problem is all B cells have this. Kills the good ones and the bad ones. ROR1 is thought to exist only on Bad B cells (CLL cells). If you make T cells using the CAR process to attack ROR1 proteins, you don't kill the good B cells. Need the good ones to make Immunoglobulins (Antibodies) to fight off infections. Keeping the good ones you will not need monthly IVIG.
I hope my explanation is what you are asking about, and if not I apologize to explain what you might already know.
Thank you - I missed the connection. So Car-t can be for any protein targeted-
for people interested to follow first ever CART approval for ALL being discussed at FDA live today. Hopefully this will pave the way for similar CLL therapy shortly
The Food and Drug Administration advisory panel voted 10-0 on Wednesday to recommend approval of the treatment developed by the University of Pennsylvania and Novartis Corp.
The one-time treatment would be for children and young adults with advanced leukemia.
This could be very good because it is a target that only appears on CLL cells and not her regular Bcells. The problem with the regular car – T therapy is it wiped out all of the B cells thus requiring IVIG injections for life.
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.